Company intelligence / Profile preview

Amnio Technology

Phoenix, Arizona, United Statesamniotechnology.com ↗

Ownership: Private
Employees: ~18
Development stage: Commercial

Overview

Amnio Technology manufactures and distributes amniotic tissue-derived products. The FDA has issued a warning letter on October 1, 2024, stating that some of their products should be regulated as drugs and biologics rather than HCT/Ps (human cell, tissue, or cellular or tissue-based products)[8][10].

Therapeutic areas: DermatologyRheumatology
Modalities: Amniotic tissue-derived allograftsAmniotic membrane productsAmniotic fluid products
Industry: Biotech

Drug pipeline

3 assets

PalinGen KardiaMembrane

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Pinnacle Transplant Technologies (contract manufacturer)[8]

Beyond the preview

Go deeper on Amnio Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amnio Technology.

Explore the full profile